In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Novo Nordisk stock tumbled Friday after its weight-loss drug Wegovy landed on Medicare's next list of drugs to face price negotiations.

OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Amgen presented data about its obesity drug at JP Morgan 2025, stating it hopes the once-monthly dosing will make it an attractive therapy.

Financing was co-led by Forbion and General Atlantic, with participants including RA Capital Management, OrbiMed, and Lilly Asia Ventures.

Users of GLP-1 drugs in the US cut their grocery spending by an average of 5.5% in the six months after taking the medication, a study shows.

We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at ...

Each diet profile includes a sample meal plan, foods to eat and avoid, tips to succeed on the diet and scientific studies that support any health benefits. The Harris Poll, our partner for this ...

Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it could happen much sooner than later. The analysts pointed to ...

The Phase IIIb SURMOUNT-5 trial found that Eli Lilly’s Zepbound was more effective in promoting weight loss than Novo Nordisk’s Wegovy. Credit: Ciara Kimsey / Shutterstock. Following positive results ...